Kristen Yen - 10 Jan 2016 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role
Officer title: Vice President, Clinical Operations
Signature
/s/ Anish Bhatnagar, Attorney-in-Fact
Issuer symbol
SLNO
Transactions as of
10 Jan 2016
Net transactions value
$0
Form type
4
Filing time
14 Oct 2022, 18:26:53 UTC
Next filing
01 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLNO Employee stock option (right to buy) Award $0 +666 $0.000000 666 10 Jan 2016 Common Stock 666 $120.75 Direct F1, F2
transaction SLNO Employee stock option (right to buy) Award $0 +1,741 $0.000000 1,741 19 Apr 2017 Common Stock 1,741 $44.25 Direct F1, F3
transaction SLNO Employee stock option (right to buy) Award $0 +5,000 $0.000000 5,000 07 Feb 2018 Common Stock 5,000 $24.00 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The per share exercise price and number of shares subject to the option reflect the 1-for-5 reverse stock split effected October 15, 2017 and the 1-for-15 reverse stock split effected August 26, 2022.
F2 One forty-eighth (1/48) of the shares subject to the Option shall vest on the first month anniversary of January 10, 2016 (the "Vesting Commencement Date"), and one forty-eighth (1/48) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
F3 Twenty-five percent (25%) of the shares subject to the Option shall vest on April 19, 2017 (the "Grant Date") and one forty-eighth (1/48) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Grant Date, such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Grant Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
F4 The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022.
F5 One forty-eighth (1/48) of the shares subject to the Option shall vest on the first month anniversary of February 7, 2018 (the "Vesting Commencement Date"), and one forty-eighth (1/48) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.

Remarks:

Officer title: Vice President, Clinical Operations